Table 4.
|
Type 2 Diabetes |
Coronary artery disease |
Congestive heart failure |
|||
---|---|---|---|---|---|---|
Intervention | Control | Intervention | Control | Intervention | Control | |
Hb1Ac (<7%) |
30.2% (n=65/215) |
29.7% (n=27/91) |
|
|
|
|
Waist circumference (<90cm women, <100cm men) |
9.8% (n=46/470) |
5.1% (n=12/234) |
11.1% (n=8/72) |
9.5% (n=4/42) |
10.8% (n=4/37) |
15.8% (n=3/19) |
Systolic blood pressure (<140mmHg) |
32.7% (n=107/327) |
35.8% (n=53/148) |
47.1% (n=24/51) |
16.1% (n=5/31) |
60.0% (n=12/20) |
0% (n=0/8) |
Diastolic blood pressure (<85mmHg) |
45.5% (n=120/264) |
37.7% (n=49/130) |
56.4% (n=22/39) |
26.1% (n=6/23) |
66.7% (n=14/21) |
53.8% (n=7/13) |
Serum total cholesterol (<4.5mmol/l) |
30.7% (n=23/75) |
35.0% (n=7/20) |
77.8% (n=7/9) |
100% (n=3/3) |
100% (n=1/1) |
0% (n=0/1) |
Serum LDL cholesterol (<2.5mmol/l) |
43.4% (n=29/67) |
47.4% (n=9/19) |
75.0% (n=6/8) |
100% (n=2/2) |
100% (n=1/1) |
(n=0) |
NYHA class (similar or improved) |
|
|
|
|
83.9% (n=26/31) |
93.3% (n=14/15) |
Target reached in at least one primary endpoint* | 47.8% (n=276/578) | 44.8% (n=125/279) | 49.5% (n=55/111) | 43.8% (n=28/64) | 75.5% (n=40/53) | 65.4% (n=17/26) |
*Intervention: 50.0% (371/742), Control: 46.1% (170/369), p = 0.217.